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Background: Artemisinin-based combination therapy (ACT) remains the most effective chemotherapeutic strategy
in the management of malaria. However, reports of reduced susceptibility of Plasmodium falciparum to the ACT
justify the need for continued search for alternative anti-malarial drugs. The use of antibiotics with anti-malarial
properties represents a potentially valuable chemotherapeutic option for the management of drug resistant
infections. Thus, the intrinsic anti-malarial activity of the combination of clinical doses of rifampicin with
amodiaquine and artemether was evaluated in an animal model using Plasmodium berghei.
Methods: A modification of the suppressive tests in vivo was employed. The anti-malarial activity of standard
doses of amodiaquine (AQ) with or without artemether (ART) and combined with varying doses of rifampicin (RIF
15 mg/kg or RIF 30 mg/kg body weight) was evaluated in 40 mice sub-divided into eight groups and inoculated
intraperitoneally with 1 × 107 red blood cells infected with chloroquine-resistant P. berghei ANKA strain. There were
two control groups of animals, one group received amodiaquine alone while the other group received saline.
Parasiticidal activity and survival of the animals were assessed over 21 days.
Results: Parasitaemia in the control animals peaked at 38% on day 9 and all animals died by day 10. The
combination of amodiaquine with rifampicin 15 mg/kg body weight was the most effective of all the combinations
and more efficacious than amodiaquine alone. The order of superiority of anti-malarial efficacy of the combinations
was as follows; AQ + RIF 15 > AQ > AQ + ART + RIF 30 > AQ + ART + RIF 15 > AQ + RIF 30.
Conclusion: The combination of the clinical dose of rifampicin (15 mg/kg) with amodiaquine represents a
potentially valuable treatment option in management of drug resistant malaria. In addition, the role of
pharmacokinetic interaction in multiple drug therapy cannot be over-emphasized.
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The World Health Organization recommends that arte-
misinin and its derivatives are combined with other anti-
malarial drugs that have different mechanisms of action
and longer half-lives in order to maximize the effective-
ness of the artemisinins and to protect them from the
development of resistance [1-3]. Artemisinin and its* Correspondence: solagbotosho@yahoo.co.uk
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unless otherwise stated.derivatives reduce most of the parasite biomass during
their initial rapid action, while an effective partner drug
can usually eliminate the small number of remaining
parasites. In addition, the probability of emergence of a
spontaneous mutation that confers resistance to two
drugs with unrelated modes of action is very low [4].
Artemisinin-based combination therapy (ACT) remains
the most effective treatment for uncomplicated Plasmo-
dium falciparum malaria. Unfortunately, Plasmodium
resistance to anti-malarial drugs continues to threaten
effective control of malaria in endemic areas. Some evi-
dence from in vitro monitoring over time in China andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Badejo et al. Malaria Journal 2014, 13:299 Page 2 of 6
http://www.malariajournal.com/content/13/1/299Viet Nam indicated increased IC-50, IC-90 or IC-99
values for artemisinins [5,6]. Furthermore, in a compari-
son of samples from Bangladesh, western Cambodia
and western and eastern Thailand, decreasing in vitro
susceptibility was observed from west to east [7]. In a
separate study in Cambodia, the highest IC-50 was re-
ported in the western part of the country [8]. Reduced
susceptibility of P. falciparum to artemisinin derivatives in
patients in western Cambodia has also been documented
[9,10]. These reports hinder malaria control initiatives and
since there are limited treatment options for the future, al-
ternative treatment strategies are urgently needed.
The use of antibiotics with anti-malarial activities rep-
resents a valuable option in malaria chemotherapeutic
strategies. Several antibiotics including tetracycline, azi-
thromycin, fluoroquinolones and rifampicin have been
shown to possess anti-malarial activity in vitro and
in vivo [11-15]. Although most of the antibiotics are
slow acting, they are best used in combination with a
more rapidly acting drug [16-19]. In a study by Dahl
and Rosenthal, clindamycin, ciprofloxacin, and azithro-
mycin but not rifampin, caused delayed death in isolates
of P. falciparum in vitro. The lower activity of the anti-
biotics has been attributed to a delayed effect of the
drugs on the parasites, which becomes progressive with
the duration of parasite-drug incubation [13,20].
Rifampicin is an antitubercular drug with potent anti-
malarial activity against Plasmodium vivax in humans
[21], Plasmodium chabaudi in rodents and chloroquine
resistant P. falciparum in vitro [22]. Combination of ri-
fampicin with isoniazid and co-trimoxazole was found to
be effective in patients with P. falciparum infections
[23]. Rifampicin appears to have a potential role to play
in the management of malaria. However, multiple drug
therapies increase the risk of pharmacokinetic drug-
drug interactions which may be of clinical relevance.
The availability of anti-malarial drugs over the counter
(including the availability of artemether, amodiaquine or
dihydroartemisinin tablets) especially in developing en-
demic countries promotes the concept of self-medication
and this further confounds the challenges of drug-drug
interaction. Rifampicin is a potent inducer of hepatic me-
tabolism and can influence pharmacokinetics of other
drugs [24] while artemisinin and its derivatives are metab-
olized by CYP 450 enzymes and can also induce the CYP
enzymes [25,26]. Induction of metabolism is mediated
mainly by the activation of the pregnane X receptor (PXR)
and the constitutive androstane receptor (CAR) [27].
The artemisinin derivatives and their metabolites differ-
entially affect the activities of CAR isoforms and of the
pregnane X receptor [28] and this may have an impact
on treatment outcome during multiple drug therapy.
Efforts in this study were thus devoted to evaluating
the interaction between rifampicin, amodiaquine andartemether in vivo during malaria infection in an animal
model using Plasmodium berghei.Methods
Drug samples
Rifampicin (RIF) was kindly provided by Bond Pharma-
ceuticals, Awe, Oyo State, Nigeria, and artemether and
amodiaquine were obtained from the Walter Reed Army
Institute for Research, USA. Stock solutions of the
compounds were prepared in distilled water and stored
at -20°C till required.Animals
The animals used in this study were male Swiss albino
mice (6 – 8 weeks old) weighing 18 – 22 grams. The ani-
mals were obtained from the animal house of the Malaria
Research Laboratories, Institute of Advanced Medical
Research and Training (IMRAT), University of Ibadan,
Ibadan. The mice were used in accordance with the NIH
Guide for the care and use of laboratory animals, NIH
publication (volume 25, number 28), revised 1996.Anti-malarial test in vivo
A modification of the suppressive tests in vivo [29] was
used. Briefly, 40 male albino mice weighing 18 – 22 g
were inoculated intraperitoneally with 1 × 107 red blood
cells infected with the CQ-resistant P. berghei ANKA
strain. The infected animals were randomly divided into
eight groups of five mice each and were treated by the
oral route with rifampicin alone at 15 or 30 mg/kg body
weight daily for seven days, amodiaquine 10 mg/kg body
weight for three days + rifampicin 15 or 30 mg/kg daily for
seven days or amodiaquine 10 mg/kg body weight for
three days + artemether 8 mg/kg daily for three days + ri-
fampicin or rifampicin 30 mg/kg body weight daily for
seven days. Two controls groups were used, one treated
with amodiaquine 10 mg/kg body weight given daily for
three days while the second group of animals were treated
with saline.
The stock solutions of the drug samples were diluted
to the desired final concentration with distilled water so
that each animal received 200 μl at time of administra-
tion of each drug. Parasiticidal activity was assessed daily
from day 3 post-infection till day 14, and then on day
21. Blood smears were prepared from the tail, methanol-
fixed, stained with Giemsa and microscopically exam-
ined by determining parasitaemia in 1,000 erythrocytes.
Mortality was monitored daily, until four weeks after in-
fection. Inhibition of parasite growth in drug-treated
group was calculated in relation to parasite growth in
the non-treated control group. All compounds and com-
binations were tested in three independent experiments.
Table 1 Survival of mice infected with chloroquine-resistant
P. berghei (ANKA) and treated with amodiaquine alone or
in combination with artemether and varying doses of
rifampicin
Treatment Group DAY 14 DAY 21
AQ 40% 40%
RIF 15 0% 0%
RIF 30 20% 20%
AQ + RIF 15 100% 60%
AQ + RIF 30 60% 0%
AQ + ART + RIF 15 60% 0%
AQ + ART + RIF 30 60% 0%
Untreated control 0% 0%
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Student-t test was used to analyse the differences in mean
parasitaemia level on days following treatment initiation,
and analysis of variance between groups (ANOVA) was
used to compare difference in percentage inhibition of
parasite growth.
Results
Parasitaemia in the untreated control animals ranged
from 2.0% on day 3 post-infection to 38.5% on day 9
when it peaked. All animals in the control group died by
day 10. Parasitaemia did not clear completely in animals
that received AQ or RIF alone. There was however, a
significant decrease in parasitaemia (54% to 86%) in the
animals treated with AQ alone during the follow up days
(days 4-9) compared with the untreated control animals
(P < 0.05) (Figure 1). In the group of animals that received
RIF 15 mg/kg or 30 mg/kg alone, significant reduction in
parasitemia (68% or 73% respectively) occurred only on
day 3 post-infection compared to the control group. Para-
sitaemia was comparable to untreated control during sub-
sequent follow-up days (P > 0.05). No mouse in the RIF
15 mg/kg group survived beyond day 12 post-inoculation
while parasitaemia kept increasing in the RIF 30 mg/kg
group until day 21 (parasitaemia = 68%) when the last
mouse died (Table 1).
Comparison of intrinsic anti-malarial activity of AQ alone
with AQ plus RIF
In the group of animals that received the combination of
AQ plus RIF (15 mg/kg), mean parasitaemia was signifi-
cantly lower (P <0.05) compared with the group of ani-
mals that received AQ only (Figure 2). In this treatment
group, mean parasitaemia in the animals was 2.5 to 7
folds lower than mean parasitaemia in the group of ani-
mals that received AQ alone, between days 5 and 9 fol-
lowing treatment (Figure 2) and remained lower till day
21. Mean parasitaemia on day 9 (when parasitaemia in
untreated control peaked at 38%) was lowest in the AQ






















Figure 1 Response of Plasmodium berghei infection in animals
to amodiaquine or varying doses of rifampicin.lower than mean parasitaemia in AQ only group (2.44 ±
0.22% vs 6.57 ± 1.65% P = 0.034). Similarly, mean parasit-
aemia on day 21 in the animals that received AQ plus
RIF (15 mg/kg) was approximately four times lower than
mean parasitaemia in animals that received AQ alone
(P < 0.05). In contrast, combination of AQ plus RIF
(30 mg/kg) did not significantly lower parasitaemia in the
animals rather response of infection in this treatment
group of animals was comparable to response of infection
in animals that received standard dose of AQ alone (P >
0.05) throughout the follow-up days (Figure 2).
Comparison of intrinsic anti-malarial activity of AQ alone
with AQ plus RIF and ART
Parasitaemia in the group of animals treated with AQ +
ART + RIF (15 mg/kg) or AQ +ART + RIF (30 mg/kg)
significantly decreased by 75% to 96% or 76% to 94%, re-
spectively, during follow up days 4 to 9 compared to the
untreated controls (P < 0.05) (Figure 3). Mean parasit-
aemia on day 9 (when parasitaemia in untreated control
peaked at 38%), in the group of animals that received
AQ +ART + RIF (15 mg/kg or 30 mg/kg) was similar to
mean parasitaemia in AQ only group (P > 0.05). Inclu-
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Figure 2 Comparative response of Plasmodium berghei
infections in mice to amodiaquine or rifampicin alone or
amodiaquine in combination with varying doses of rifampicin.
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Figure 3 Comparative response of Plasmodium berghei
infections in mice to amodiaquine or rifampicin alone or
amodiaquine in combination with varying doses of rifampicin
and artemether.
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treatment.
Survival rate of animals
The survival rate of animals after treatment with AQ
alone or in combination with varying doses of RIF and
ART was assessed on days 14 and 21 and are presented
on Table 1. The day 14 survival rate was highest (100%)
in the group of animals that received AQ + RIF (15 mg/
kg) while Day 14 survival rate was lowest in the group of
animals that received AQ+RIF (30 mg/kg). Day 21 sur-
vival rate was 60% in the AQ+ RIF (15 mg/kg) group, 40%
in animals treated with AQ and 20% in the RIF 30 mg/kg
group. No animal survived in the RIF 15 mg/kg, AQ+ RIF
(30 mg/kg) and ART + RIF (15 mg/kg or 30 mg/kg) treat-
ment groups during the 21 day follow up.
Discussion
Rifampicin a major component of combination treat-
ment regimen for tuberculosis is derived from rifampicin
B which is produced by Streptomyces mediterranei [24].
It is an antibiotic which has been shown to possess anti-
malarial activity in vivo and in vitro in various experimen-
tal studies; Rifampicin is effective against P. chabaudi and
P. berghei in rodents and chloroquine resistant P. falcip-
arum in vitro [12,13,22,30]. Furthermore, beneficial inter-
action between rifampin and primaquine against P. vivax
infection in humans has also been reported [21]. In that
report, rifampin given at the usual dose of 15-20 mg/kg/
day alone was active against the blood stage infection of
human P. vivax malaria decreasing but not clearing
parasitaemia.
This study describes beneficial interaction between amo-
diaquine and rifampicin in mice infected with chloroquine
resistant strains of P. berghei. The interaction was demon-
strated by a significant reduction in parasitaemia and
enhanced survival rate of the animals (100% and 60% on
day 14 and 21 respectively) in the group of animals
treated with the combination of AQ plus 15 mg/kg body
weight RIF. This is the first report describing beneficialinteraction between RIF and AQ. Rifampicin alone given
at standard clinical doses (15-30 mg/kg) in this study
exhibited slight anti-malarial activity against P. berghei,
as no substantial drop in parasitaemia was observed as
reported in previous studies [22]. Strath et al. reported a
clear dose-response effect of rifampicin with substantial
drop in peripheral parasitaemia of P. chabaudi within
24 hrs of treatment following the use of 100-200 mg/kg
body weight rifampicin. This dose is six folds higher
than the dose employed in the present study. In a study
by Schmidt, doses of rifampicin up to 20 mg/kg failed to
effect cures or prevent relapses when combined with
chloroquine [31].
The beneficial interaction between amodiaquine and
rifampicin observed in this study especially at doses of
rifampicin used clinically in the management of tuber-
culosis is a welcome discovery as co-existence between
TB and malaria leads to various concerns about their
treatment. The suitability of rifampicin rather than
tetracycline for the treatment of children might be of
particular interest in the potential clinical use of the
combination. The combination of amodiaquine with
15 mg/kg bodyweight of rifampicin in this study was su-
perior to the combination with 30 mg/kg bodyweight of
rifampicin in reducing peripheral parasitaemia and en-
hancing survival rate. The reason for this disparity is
not clear but it may not be unconnected with the auto-
inducing effects of rifampicin which may also be dose
related. Rifampicin is a great CYP450 inducer and one
of the most potent inducers of all drugs used clinically
[24]. Thus a decreased drug plasma concentration may
result as rifampicin stimulates its own metabolism to in-
active metabolites.
It would have been expected that the inclusion of arte-
mether, a rapidly acting anti-malarial drug in the com-
bination would produce a more significant effect in
terms of enhanced parasite clearance and survival rate.
Surprisingly, presence of artemether in the combination
of amodiaquine with rifampicin did not produce a more
superior anti-malarial effect over AQ + RIF 15 or AQ
alone against the parasites. Superiority of the combin-
ation was as follows AQ + RIF 15 > AQ > AQ + ART +
RIF30 > AQ + ART + RIF15 > AQ + RIF 30. The poten-
tial for drug-drug interaction cannot be overemphasized
during combination or multiple drug therapy as it may
pose serious challenges to treatment outcome. The lack
of the expected enhanced anti-malarial effects when
artemether was included in the combination may be as
a result of pharmacokinetic interaction. Rifampicin is a
potent inducer of hepatic and intestinal CYP450 enzyme
activity (CYP3A4, CYP2C9, CYP2C8, CYP2C18/19) and
all artemisinin derivative compounds are metabolized by
the CYP450 enzymes to the active dihydroartemisinin,
also available as a drug itself [25]. The artemisinins also
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own metabolism [25,26]. Similarly, rifampicin is an auto-
inducer stimulating its own metabolism into inactive
metabolites [32]. Thus, concomitant administration of ri-
fampicin with artemether may lead to an extensive time-
dependent decline in drug plasma concentrations and a
potential decrease in efficacy as a result of auto-inducing
interplay between both drugs. This explanation is cor-
roborated by a report by Lamorde et al. who reported
unfavourable pharmacokinetic interaction between arte-
mether, lumefantrine and rifampicin in healthy adults
[33]. In that study, the area under the concentration-time
curve (AUC) of artemether and dihydroartemisinin, which
is a measure of exposure to drug was decreased by 89%
during rifampicin treatment. In addition, the maximum
plasma concentration of artemether and dihydroartemisi-
nin were reduced by 83% in the presence of rifampicin.
Bioavailability is concerned with how quickly and how
much of a drug appears in the blood after a specific dose
is administered and it often determines therapeutic effi-
cacy since it affects the onset, intensity and duration of
therapeutic response of the drug. Thus reduced plasma
concentration and bioavailability of artemether in the
presence of rifampicin may have contributed to the in-
ability of the combination of amodiaquine/rifampicin/
artemether to produce the expected enhanced effects
against P. berghei in the present study. Similarly, reports
of pharmacokinetic interaction between rifampicin and
quinine which adversely affects the efficacy of quinine
in uncomplicated falciparum malaria have been docu-
mented [34]. Pharmacokinetic interaction between ri-
fampicin and quinidine or mefloquine have also been
reported resulting in increased oral clearance of the
anti-malarial drugs [35,36].
Theoretically it would be expected that rifampicin
would alter amodiaquine activity when co-administered
because amodiaquine is metabolized by CYP2C8, an en-
zyme also inducible by rifampicin. However this was not
the case, as amodiaquine activity was significantly en-
hanced in the presence of rifampicin 15 mg/kg by enhan-
cing the rate of fall in parasitaemia and survival rate of the
animals. The higher dose rifampicin (30 mg/kg) did not
appear to induce metabolism of AQ either, as response of
infection to AQ + RIF30 was similar to that of AQ alone.
Rifampicin auto induction, which seems to be dose
dependent appears to be a plausible explanation.
In conclusion, this study reveals a beneficial effect of
rifampicin in combination with amodiaquine against a
chloroquine-resistant strain of P. berghei and provides a
potentially useful chemotherapeutic alternative in the
management of malaria in endemic areas. Detailed phar-
macokinetic and toxicological studies on the interaction
between amodiaquine and rifampicin are required prior
to clinical application of the combination.Competing interests
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